financetom
Business
financetom
/
Business
/
Firm gold price helping co on collateral safety side; Belstar showing promise: Muthoot Finance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Firm gold price helping co on collateral safety side; Belstar showing promise: Muthoot Finance
Mar 29, 2022 3:48 AM

Muthoot Finance is expanding into the microfinance space through its arm Belstar. There will be an equity infusion of Rs 275 crore into Belstar and Muthoot’s stake post the fund infusion will be around 60 percent.

To understand the company's rationale in entering the microfinance space, CNBC-TV18 spoke to George Alexander Muthoot, MD, Muthoot Finance.

Muthoot explained the rationale behind the company’s decision to expand in the microfinance space. He said that purchasing power at lower levels is through microfinance and that the public needs it. He added that Belstar has done a good job in running its business as well hence the company decided to invest money into it. However, he clarified that the company’s investments in microfinance institutions is miniscule.

"We always felt that microfinance is something which is definitely needed by the public and it is the best way to put money in the hands of people. Purchasing power at the lower level is through microfinance and microfinance have done a good job there," he said.

"Belstar has done a fine job till now. That is why we are also putting additional capital. The investment in MFI is just a small trickle. Our net worth is more than Rs 16,000 crore and the investment in MFI is only about Rs 50 crore. It's just a miniscule part," he said.

Also Read:

Gold, silver prices down on hopes of Russia-Ukraine peace talks, easing oil prices

He mentioned that firm gold prices have helped the company on the collateral safety side. Q4 has been good and the upcoming quarters look promising, he mentioned.

"On the collateral safety side, gold price is holding up, that is definitely helping us on the collateral side. But then it is the demand also. The demand for gold loan has started picking up, Q3 was good but we had to auction quite a lot of money. But still we were able to maintain the level even with the auctions," he said.

"Q4 has also been good. And we see next quarters, that is Q1, Q2 of next year to be quite promising because economic activity has really started picking up.," he added.

Watch the video for the full interview.

Catch all stock market updates here

First Published:Mar 29, 2022 12:48 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vista Outdoor Says MNC Capital's Pressure Led to Withdrawal of Higher Bid for The Kinetic Group
Vista Outdoor Says MNC Capital's Pressure Led to Withdrawal of Higher Bid for The Kinetic Group
Jun 17, 2024
08:49 AM EDT, 06/17/2024 (MT Newswires) -- Vista Outdoor ( VSTO ) said Monday that a US investment firm's roughly $2.01 billion alternative acquisition proposal for The Kinetic Group has been withdrawn due to pressure from MNC Capital Partners. The sporting and outdoor products company said that MNC alleged that the alternate party violated prior contractual agreements made during a...
What's Going On With Workhorse Group Stock Monday?
What's Going On With Workhorse Group Stock Monday?
Jun 17, 2024
Workhorse Group Inc ( WKHS ) shares are in the spotlight Monday as the stock begins trading on a split-adjusted basis. Here’s a look at what you need to know. What To Know: Workhorse announced a 1-for-20 reverse stock split of its common stock last week after shareholders approved the move at the company’s annual meeting of stockholders in May....
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer
Jun 17, 2024
08:51 AM EDT, 06/17/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that it had submitted a Biologics License Application to the US Food and Drug Administration for subcutaneous amivantamab for certain patients with non-small cell lung cancer. The company said the application is based on a late-stage study that showed that the subcutaneous form was as...
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails
Jun 17, 2024
June 17 (Reuters) - Aerovate Therapeutics ( AVTE ) said on Monday it is shutting down the late-stage portion of a study testing its experimental hypertension drug after failing to meet the main goal in a mid-stage trial. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved